For instance, Cenicriviroc, a dual antagonist of CCR2 and CCR5 receptors, yielded satisfactory results in the first year of its phase II clinical trial, showing a significant reduction in systemic inflammation and markers of inflammation in NASH [75]. Here, CCR2 is linked to metabolic dysfunction-associated steatohepatitis.